BGLAF (BioGaia AB) Cyclically Adjusted Revenue per Share: $1.14 (As of Mar. 2026)


BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $12.61
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioGaia AB Cyclically Adjusted Revenue per Share?

BioGaia AB BGLAF 100 Cyclically Adjusted Revenue per Share is $1.14 as of Mar. 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.61 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioGaia AB's adjusted revenue per share for the three months ended in Mar. 2026 was $0.395. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.14 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioGaia AB's average Cyclically Adjusted Revenue Growth Rate was 7.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioGaia AB was 12.90% per year. The lowest was 9.70% per year. And the median was 11.00% per year.

As of today (2026-07-01), BioGaia AB's current stock price is $12.20. BioGaia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.14. BioGaia AB's Cyclically Adjusted PS Ratio of today is 10.70.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioGaia AB was 18.84. The lowest was 8.61. And the median was 12.72.


BioGaia AB  (OTCPK:BGLAF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioGaia AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.20/1.14
=10.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioGaia AB was 18.84. The lowest was 8.61. And the median was 12.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioGaia AB Cyclically Adjusted Revenue per Share Related Terms


BioGaia AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Cyclically Adjusted Revenue per Share Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 1.03 0.97 0.90 1.17

BioGaia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.99 1.08 1.17 1.14

BGLAF vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Cyclically Adjusted PS Ratio falls into.


BGLAF
100GF Score
BioGaia AB BGLAF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioGaia AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.395/133.3862*133.3862
=0.395

Current CPI (Mar. 2026) = 133.3862.

BioGaia AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.189 101.019 0.250
201609 0.170 101.138 0.224
201612 0.174 102.022 0.227
201703 0.182 102.022 0.238
201706 0.207 102.752 0.269
201709 0.213 103.279 0.275
201712 0.234 103.793 0.301
201803 0.219 103.962 0.281
201806 0.234 104.875 0.298
201809 0.226 105.679 0.285
201812 0.311 105.912 0.392
201903 0.213 105.886 0.268
201906 0.272 106.742 0.340
201909 0.198 107.214 0.246
201912 0.246 107.766 0.304
202003 0.214 106.563 0.268
202006 0.301 107.498 0.373
202009 0.170 107.635 0.211
202012 0.236 108.296 0.291
202103 0.234 108.360 0.288
202106 0.239 108.928 0.293
202109 0.198 110.338 0.239
202112 0.225 112.486 0.267
202203 0.294 114.825 0.342
202206 0.284 118.384 0.320
202209 0.234 122.296 0.255
202212 0.262 126.365 0.277
202303 0.346 127.042 0.363
202306 0.290 129.407 0.299
202309 0.284 130.224 0.291
202312 0.287 131.912 0.290
202403 0.352 132.205 0.355
202406 0.363 132.716 0.365
202409 0.294 132.304 0.296
202412 0.328 132.987 0.329
202503 0.357 132.825 0.359
202506 0.419 133.699 0.418
202509 0.344 133.482 0.344
202512 0.469 133.386 0.469
202603 0.395 133.386 0.395

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.14 mean?
BioGaia AB (BGLAF) has a Cyclically Adjusted Revenue per Share of $1.14 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioGaia AB and its competitors.
Is BioGaia AB's Cyclically Adjusted Revenue per Share too high?
BioGaia AB's current Cyclically Adjusted Revenue per Share is $1.14. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
BioGaia AB's Cyclically Adjusted Revenue per Share of $1.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioGaia AB and its competitors. BioGaia AB's current Cyclically Adjusted Revenue per Share is $1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.61, compared to a current price of $12.20 — trading 3.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.14. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Cyclically Adjusted Revenue per Share is $1.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 3.3% below its estimated GF Value™ of $12.61. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BGLAF:

  • Cyclically Adjusted Revenue per Share: $1.14
  • GF Value™: $12.61 vs. price of $12.20 (3.3% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$12.61
GF Value